<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04000529</url>
  </required_header>
  <id_info>
    <org_study_id>CTNO155B12101</org_study_id>
    <nct_id>NCT04000529</nct_id>
  </id_info>
  <brief_title>Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies</brief_title>
  <official_title>A Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase Ib, multi-center, open-label study of TNO155 in combination with&#xD;
      spartalizumab or ribociclib with a dose escalation part followed by a dose expansion part in&#xD;
      adult subjects with advanced solid tumors.&#xD;
&#xD;
      These two treatment arms will enroll subjects in parallel to characterize the safety,&#xD;
      tolerability, PK, PD and preliminary antitumor activity.&#xD;
&#xD;
      The study treatment will be administered until the subject experiences unacceptable toxicity,&#xD;
      progressive disease, and/or has treatment discontinued at the discretion of the Investigator&#xD;
      or the subject, or due to withdrawal of consent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale The purpose of this study is to evaluate the safety, tolerability, and preliminary&#xD;
      efficacy of the combination of TNO155 with spartalizumab and of TNO155 with ribociclib, and&#xD;
      to identify dosing regimens for further study. Data from preclinical models have demonstrated&#xD;
      anti-tumor activity for the combinations of TNO155 with spartalizumab and of TNO155 with&#xD;
      ribociclib that is superior to the activity observed with each of the drugs as single agents.&#xD;
      These data suggest that these combinations may provide clinical benefit to patients with&#xD;
      advanced malignancies.&#xD;
&#xD;
      Study Design This study is a Phase Ib, multi-center, open-label study with a dose escalation&#xD;
      part followed by a dose expansion part in adult subjects with advanced solid tumors to&#xD;
      characterize the safety and tolerability TNO155 in combination with spartalizumab and of&#xD;
      TNO155 in combination with ribociclib and to identify the MTD and/or recommended regimen&#xD;
      (dose and schedule) for each combination. The study treatment will be administered until the&#xD;
      subject experiences unacceptable toxicity, progressive disease, and/or has treatment&#xD;
      discontinued at the discretion of the Investigator or the subject, or due to withdrawal of&#xD;
      consent.&#xD;
&#xD;
      Objectives&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To characterize the safety and tolerability TNO155 in combination with spartalizumab and of&#xD;
      TNO155 in combination with ribociclib, and to identify the MTD and/or recommended regimen&#xD;
      (dose and schedule) for each combination.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To characterize the pharmacokinetic (PK) profile of TNO155, spartalizumab and ribociclib&#xD;
           when administered as a combination of TNO155 plus spartalizumab or of TNO155 plus&#xD;
           ribociclib.&#xD;
&#xD;
        -  To evaluate the preliminary anti-tumor activity of TNO155 in combination with&#xD;
           spartalizumab and of TNO155 in combination with ribociclib.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2019</start_date>
  <completion_date type="Anticipated">October 12, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 12, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT incidence</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of dose limiting toxicities (DLTs) during the first cycle of combination treatment during the dose escalation part</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AE and SAE incidence</measure>
    <time_frame>3 years</time_frame>
    <description>Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as per CTCAE v5.0, by treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose interruptions, reductions and dose intensity, by treatment</measure>
    <time_frame>3 years</time_frame>
    <description>Dose tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Cmax</measure>
    <time_frame>3 years</time_frame>
    <description>Cmax for TNO155, spartalizumab, and ribociclib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Tmax</measure>
    <time_frame>3 years</time_frame>
    <description>Tmax for TNO155, spartalizumab, and ribociclib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): AUClast</measure>
    <time_frame>3 years</time_frame>
    <description>AUClast for TNO155, spartalizumab, and ribociclib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): AUCtau</measure>
    <time_frame>3 years</time_frame>
    <description>AUCtau for TNO155, spartalizumab, and ribociclib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy measurements per RECIST v1.1: ORR</measure>
    <time_frame>3 years</time_frame>
    <description>Overall response rate (ORR) per RECIST v1.1, by treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy measurements per RECIST v1.1: DCR</measure>
    <time_frame>3 years</time_frame>
    <description>Disease control rate (DCR) per RECIST v1.1, by treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy measurements per RECIST v1.1: PFS</measure>
    <time_frame>3 years</time_frame>
    <description>Progression-free survival (PFS) per RECIST v1.1, by treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy measurements per RECIST v1.1: DOR</measure>
    <time_frame>3 years</time_frame>
    <description>Duration of response (DOR) per RECIST v1.1, by treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy measurements per iRECIST: ORR</measure>
    <time_frame>3 years</time_frame>
    <description>Overall response rate (ORR) per iRECIST for TNO155 in combination with spartalizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy measurements per iRECIST: DCR</measure>
    <time_frame>3 years</time_frame>
    <description>Disease control rate (DCR) per iRECIST for TNO155 in combination with spartalizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy measurements per iRECIST: PFS</measure>
    <time_frame>3 years</time_frame>
    <description>Progression-free survival (PFS) per iRECIST for TNO155 in combination with spartalizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy measurements per iRECIST: DOR</measure>
    <time_frame>3 years</time_frame>
    <description>Duration of response (DOR) per iRECIST for TNO155 in combination with spartalizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival (OS) by treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Non-small Cell Lung Carcinoma</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Esophageal SCC</condition>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>TNO155 in combination with spartalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TNO155 in combination with spartalizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TNO155 in combination with ribociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TNO155 in combination with ribociclib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNO155</intervention_name>
    <description>Capsule</description>
    <arm_group_label>TNO155 in combination with ribociclib</arm_group_label>
    <arm_group_label>TNO155 in combination with spartalizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spartalizumab</intervention_name>
    <description>Concentrate for solution for infusion</description>
    <arm_group_label>TNO155 in combination with spartalizumab</arm_group_label>
    <other_name>PDR001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib</intervention_name>
    <description>Capsule and tablet</description>
    <arm_group_label>TNO155 in combination with ribociclib</arm_group_label>
    <other_name>LEE011</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent must be obtained prior to participation in the study.&#xD;
&#xD;
          2. Age ≥ 18 years. For Japan only: written consent is necessary both from the patient and&#xD;
             his/her legal representative if he/she is under the age of 20 years.&#xD;
&#xD;
          3. ECOG (Eastern Cooperative Oncology Group) performance status ≤ 1.&#xD;
&#xD;
          4. Dose escalation part: Patients with advanced solid tumors, with evaluable disease as&#xD;
             determined by RECIST version 1.1, and fit into one of the following groups:&#xD;
&#xD;
             a. For TNO155 plus spartalizumab combination: i. Advanced EGFR WT, ALK WT NSCLC, after&#xD;
             progression on or intolerance to platinum-containing combination chemotherapy and&#xD;
             after progression on anti-PD-1 or anti-PD-L1 therapy.&#xD;
&#xD;
             ii. Advanced HNSCC or esophageal SCC, after progression on or intolerance to&#xD;
             platinum-containing combination chemotherapy.&#xD;
&#xD;
             iii. Advanced CRC, after progression on or intolerance to all standard-of-care (SOC)&#xD;
             therapy per local guidelines.&#xD;
&#xD;
             b. For TNO155 plus ribociclib combination: i. Advanced NSCLC, after progression on or&#xD;
             intolerance to platinum-containing combination chemotherapy and anti-PD-1 or&#xD;
             anti-PD-L1 therapy.&#xD;
&#xD;
             ii. Advanced HNSCC or esophageal SCC after progression on or intolerance to,&#xD;
             platinum-containing combination chemotherapy and anti-PD-1 or anti-PD-L1 therapy,&#xD;
             where such therapy is available and considered standard of care.&#xD;
&#xD;
             iii. Advanced CRC or GIST, after progression on or intolerance to all SOC therapy per&#xD;
             local guidelines.&#xD;
&#xD;
          5. Dose expansion part: Patients with advanced solid tumors, with at least one measurable&#xD;
             lesion as determined by RECIST version 1.1, who fit into one of the following groups:&#xD;
&#xD;
             a. For TNO155 plus spartalizumab combination: i. Advanced EGFR WT, ALK WT, KRAS G12C&#xD;
             NSCLC after progression on or intolerance to platinum-containing combination&#xD;
             chemotherapy and after progression on anti-PD-1 or anti-PD-L1 therapy.&#xD;
&#xD;
             ii. Advanced EGFR WT, ALK WT, KRAS WT NSCLC, after progression on or intolerance to&#xD;
             platinum-containing combination chemotherapy and after progression on anti-PD-1 or&#xD;
             anti-PD-L1 therapy.&#xD;
&#xD;
             iii. Advanced HNSCC, after progression on or intolerance to, platinum-containing&#xD;
             combination chemotherapy.&#xD;
&#xD;
             b. For TNO155 plus ribociclib combination: i. Advanced EGFR WT, ALK WT, KRAS WT NSCLC,&#xD;
             after progression on or intolerance to platinum-containing chemotherapy and anti-PD-1&#xD;
             or anti-PD-L1 therapy ii. Advanced CRC harboring a KRAS codon 12, 13, or 61 mutation,&#xD;
             after progression on or intolerance to all SOC per local guidelines&#xD;
&#xD;
          6. Patients with NSCLC whose tumors harbor genomic aberrations for which SOC targeted&#xD;
             therapies exist and are locally approved and available must have had progression on or&#xD;
             after, or intolerance to, the SOC targeted therapy/therapies as indicated&#xD;
&#xD;
          7. Patients must have a site of disease amenable to biopsy&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with a MAPK pathway inhibitor&#xD;
&#xD;
          2. Clinically significant cardiac disease or risk factors&#xD;
&#xD;
          3. Use of any agent known to prolong the QT interval unless it can be permanently&#xD;
             discontinued for the duration of study (see list in Section 6.2.2).&#xD;
&#xD;
          4. History or current evidence of retinal vein occlusion (RVO) or current risk factors&#xD;
             for RVO&#xD;
&#xD;
          5. Inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease) or impairment&#xD;
             of gastrointestinal (GI) function or GI disease that may significantly alter the&#xD;
             absorption of study drugs&#xD;
&#xD;
          6. Symptomatic CNS metastases which are neurologically unstable&#xD;
&#xD;
          7. Insufficient bone marrow function at screening:&#xD;
&#xD;
               1. Absolute Neutrophil Count (ANC) &lt; 1.5 x 109/L.&#xD;
&#xD;
               2. Hemoglobin &lt; 9.0 g/dL.&#xD;
&#xD;
               3. Platelets &lt; 75 x 109/L for TNO155 plus spartalizumab combination; &lt; 100 x 109/L&#xD;
                  for TNO155 plus ribociclib combination.&#xD;
&#xD;
          8. Insufficient hepatic or renal function at screening:&#xD;
&#xD;
               1. Serum total bilirubin &gt; upper limit of normal (ULN) or, for TNO155 plus&#xD;
                  spartalizumab combination only, if liver metastases are present at baseline,&#xD;
                  serum total bilirubin &gt; 1.5 x ULN. An exception for either combination is for&#xD;
                  patients with Gilbert's syndrome, who are excluded if total bilirubin &gt; 3.0 x ULN&#xD;
                  or direct bilirubin &gt; 1.5 x ULN&#xD;
&#xD;
               2. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 3 x ULN for&#xD;
                  TNO155 plus spartalizumab combination or &gt; 2.5 x ULN for TNO155 plus ribociclib&#xD;
                  combination, or &gt; 5 x ULN for either combination if liver metastases are present.&#xD;
&#xD;
               3. Creatinine clearance &lt; 60 mL/min (calculated using Cockcroft-Gault equation).&#xD;
&#xD;
          9. Pregnant or breast-feeding (lactating) women.&#xD;
&#xD;
             Additional exclusion criteria for the TNO155 plus spartalizumab combination&#xD;
&#xD;
         10. History of severe hypersensitivity reactions to other mAbs.&#xD;
&#xD;
         11. Active, known or suspected autoimmune disease.&#xD;
&#xD;
         12. History of or current interstitial lung disease or pneumonitis grade ≥ 2.&#xD;
&#xD;
         13. Human Immunodeficiency Virus (HIV) infection, unless the patient is on antiviral&#xD;
             therapy and has undetectable viral load.&#xD;
&#xD;
         14. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.&#xD;
&#xD;
         15. Systemic chronic steroid therapy&#xD;
&#xD;
         16. Patients who discontinued prior anti-PD-1 therapy due to an anti-PD-1-related&#xD;
             toxicity.&#xD;
&#xD;
             Additional exclusion criteria for the TNO155 plus ribociclib combination&#xD;
&#xD;
         17. Systolic Blood Pressure (SBP) &lt; 90 mmHg.&#xD;
&#xD;
         18. International Normalized Ratio (INR) &gt; 1.5 (unless the patient is receiving&#xD;
             anticoagulants and the INR is within the therapeutic range of intended use for that&#xD;
             anticoagulant within seven days prior to the first dose of study drug).&#xD;
&#xD;
         19. History of HIV infection (testing not mandatory)&#xD;
&#xD;
         20. Currently receiving any of the following substances and cannot be discontinued seven&#xD;
             days prior to Cycle 1 Day 1:&#xD;
&#xD;
               -  Concomitant medications or herbal supplements, that are strong inducers or&#xD;
                  inhibitors of CYP3A4/5,&#xD;
&#xD;
               -  Medications that have a narrow therapeutic window and are predominantly&#xD;
                  metabolized through CYP3A4/5.&#xD;
&#xD;
         21. Previous treatment with a CDK4/6 inhibitor.&#xD;
&#xD;
         22. Patient is currently receiving or has received systemic corticosteroids ≤ 2 weeks&#xD;
             prior to starting study drug, or who have not fully recovered from side effects of&#xD;
             such treatment.&#xD;
&#xD;
        Note: The following uses of corticosteroids are permitted: single doses, topical&#xD;
        applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye&#xD;
        drops or local injections (e.g., intra-articular).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Cournoyer</last_name>
      <phone>617-726-5276</phone>
      <email>MCOURNOYER@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Jessica Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo ku</city>
        <state>Tokyo</state>
        <zip>104 0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>China</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Finland</country>
    <country>Korea, Republic of</country>
    <country>Norway</country>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2019</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TNO155, spartalizumab, ribociclib, checkpoint inhibitor, SHP2, PD-1, CDK4/6, NSCLC, CRC, HNSCC, KRAS, esophageal SCC, GIST</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spartalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

